Cisplatin-Based Chemotherapy for Pulmonary Metastasized Germ Cell Tumors of the Testis – Be Aware of Acute Respiratory Distress Syndrome

Background: Cisplatin-based combination chemotherapy is regarded as standard of care for patients with advanced germ cell tumors. In patients with lung metastases and a high tumor load, an association between induction chemotherapy and the development of a ‘tumorassociated’ acute respiratory distress syndrome (ARDS) has been hypothesized. Case Report: We report the clinical course of a 19-year-old patient who rapidly developed fatal ARDS during the first cycle of chemotherapy using the PEI regimen (cisplatin, etoposide and ifosfamide) for a metastasized (lung, liver, lymph nodes) germ cell tumor of the testis. Conclusion: Further clinical research in order to better define risk factors for developing ARDS in this patient population as well as novel strategies for the prevention and treatment of ARDS in those patients are necessary.

[1]  J. Droz,et al.  Management of advanced germ-cell tumors of the testis , 2008, Nature Clinical Practice Urology.

[2]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. , 2008, European urology.

[3]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. , 2008, European urology.

[4]  S. Culine,et al.  Chemotherapy for poor prognosis non seminomatous germ cell tumors (NSGCT): Should doses be reduced at first cycle to prevent acute respiratory distress syndrome (ARDS) in patients with multiple lung metastases? , 2007 .

[5]  W. Voigt,et al.  Human Chorionic Gonadotropin-Induced Hyperthyroidism in Germ Cell Cancer – a Case Presentation and Review of the Literature , 2007, Oncology Research and Treatment.

[6]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.

[7]  S. Culine,et al.  Super-high-risk germ-cell tumors: a clinical entity , 1994, Supportive Care in Cancer.

[8]  W. Wilmanns,et al.  Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  M. Pratter,et al.  Primary testicular choriocarcinoma with pulmonary metastases presenting as ARDS. , 1990, Chest.